Imetelstat + Ruxolitinib

About Geron

Geron is a commercial-stage biotech focused on developing and commercializing first-in-class telomerase inhibitors for blood cancers. Its science is grounded in the Nobel Prize-winning discoveries of telomeres and telomerase. With its drug imetelstat now approved in the U.S. for certain myelodysplastic syndromes (MDS) patients and a pivotal Phase 3 trial ongoing in myelofibrosis (MF), Geron is positioned to potentially transform the treatment landscape for several difficult-to-treat myeloid malignancies.

Therapeutic Areas